ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,946 GBX | +0.29% |
|
-1.07% | +3.26% |
| Apr. 17 | AstraZeneca: presents new data at ECCMID | CF |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
ETFs positioned on AstraZeneca PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +11.13% | ||
| 5.17% | 18 M€ | +1.40% | - | |
| 4.89% | 776 M€ | +6.35% | ||
| 4.11% | 88 M€ | +10.37% | - | |
| 3.47% | 233 M€ | +6.49% | ||
| 2.74% | 4 M€ | -.--% | - | |
| 2.57% | 6 M€ | -.--% | ||
| 2.53% | 5 M€ | 0.00% | - | |
| 2.53% | 1,331 M€ | +4.98% | ||
| 1.54% | 29 M€ | +8.37% | - | |
| 1.51% | 2 M€ | +9.19% | - | |
| 1.51% | 2 M€ | -.--% | - | |
| 1.26% | 12 M€ | +15.09% | - | |
| 1.19% | 49 M€ | +3.53% | ||
| 1.16% | 10 M€ | -3.35% | - | |
| 0.97% | 7 M€ | -0.20% | - | |
| 0.89% | 31 M€ | +1.43% | - | |
| 0.86% | 276 M€ | +11.40% | - | |
| 0.70% | 277 M€ | -.--% | - | |
| 0.69% | 194 M€ | +4.96% | - | |
| 0.69% | 441 M€ | +7.56% | ||
| 0.57% | 205 M€ | -.--% | ||
| 0.54% | 284 M€ | -.--% | ||
| 0.51% | 23 M€ | -.--% | - | |
| 0.51% | 786 M€ | -.--% | ||
| 0.50% | 206 M€ | -.--% | ||
| 0.48% | 717 M€ | +4.39% | ||
| 0.43% | 273 M€ | +11.25% |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
136
USD
Average target price
162
USD
Spread / Average Target
+19.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.26% | 211B | |
| +25.02% | 672B | |
| +24.08% | 550B | |
| -6.30% | 351B | |
| +15.07% | 317B | |
| +7.35% | 292B | |
| +0.78% | 203B | |
| -10.25% | 144B | |
| -7.24% | 141B | |
| -3.20% | 113B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC
